In 2026, Pfizer faces significant pressure in the emerging GLP-1 weight-loss drug segment, where early leaders have secured the majority of market share. While Pfizer’s late-stage candidate completed Phase III trials last quarter, analysts project it will not reach peak annual sales of $10 billion until 2029, by which time established competitors are expected to command over 70% of the global market. This delay threatens to leave a multi-billion-dollar revenue opportunity untapped during a critical growth window and could force Pfizer to consider accelerated partnerships or licensing deals to improve its market positioning.

Pfizer’s two highest-grossing products, Ibrance and Eliquis, will face patent expiry in late 2027 and 2028 respectively, with Vyndaqel set to join the list in 2028. Ibrance and Eliquis collectively generated approximately $17.5 billion in combined global sales last year, representing more than 25% of total company revenue. The imminent entry of biosimilars and generics could erode those sales by up to 60% within 12 months of exclusivity loss, according to industry consulting firm EvaluatePharma. Pfizer has earmarked R&D spending of nearly $10 billion for 2026 to advance follow-on molecules, but investors remain cautious about the shortfall in near-term cash flow once core patents expire.

Pfizer’s current annual dividend of $1.72 per share implies a payout ratio approaching 100% of expected 2026 adjusted earnings per share of $1.75, based on consensus forecasts. This represents a steep increase from a 53% payout ratio reported in 2023. With free cash flow projected to decline by nearly $4 billion year-over-year due to lower vaccine revenue and upcoming patent losses, dividend coverage could become strained. While management has signaled commitment to its dividend policy, conservative income investors should monitor cash flow trends closely for any adjustments in the quarterly distribution.